(NASDAQ: RZLT) Rezolute's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.65%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.44%.
Rezolute's earnings in 2026 is -$77,586,000.On average, 13 Wall Street analysts forecast RZLT's earnings for 2027 to be -$69,688,441, with the lowest RZLT earnings forecast at -$81,517,582, and the highest RZLT earnings forecast at -$57,888,316. On average, 12 Wall Street analysts forecast RZLT's earnings for 2028 to be -$51,108,081, with the lowest RZLT earnings forecast at -$91,944,250, and the highest RZLT earnings forecast at -$15,233,767.
In 2029, RZLT is forecast to generate -$72,019,449 in earnings, with the lowest earnings forecast at -$390,526,092 and the highest earnings forecast at $69,059,746.